Drug data last refreshed 44m ago · AI intelligence enriched 1w ago
NICORETTE is a nicotine polacrilex lozenge indicated for smoking cessation as a nicotinic cholinergic agonist. It delivers nicotine orally via a troche formulation to reduce cravings and withdrawal symptoms in patients attempting to quit smoking. The drug works by binding to nicotinic acetylcholine receptors to provide substitution therapy during smoking cessation.
Product is at peak lifecycle stage with formulation patent expiry in 3 years, signaling transition planning and potential team restructuring.
Cholinergic Nicotinic Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers
Clinical Study to Assess Bioequivalence Between Nicorette Extra Mint Gum and Nicorette® Mint Gum in Healthy Smokers
"EASY EFFECTIVE SMOKELESS" With NICORETTE®
Bioequivalence Between an Oral Nicotine Replacement Product and Nicorette® Gum
Evaluation of the Safety Profile, Quit and Reduction Rate After Nicorette® Gum and Patch Treatment
Worked on NICORETTE at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
NICORETTE represents a mature, commercially stable product with established market presence, but limited career growth opportunities given zero linked job postings and approaching loss of exclusivity. Professionals joining this franchise would focus on defending market share and optimizing profitability in the final 3 years before generic competition.